Sidoti upgraded shares of USANA Health Sciences (NYSE:USNA) from a neutral rating to a buy rating in a research note released on Thursday, Marketbeat reports.
Separately, Pivotal Research upgraded USANA Health Sciences from a hold rating to a buy rating and set a $135.00 price objective for the company in a report on Wednesday, October 24th. One analyst has rated the stock with a sell rating and three have issued a buy rating to the company’s stock. USANA Health Sciences has a consensus rating of Buy and a consensus price target of $135.00.
Shares of USNA opened at $108.59 on Thursday. The firm has a market capitalization of $2.63 billion, a price-to-earnings ratio of 26.75 and a beta of 0.61. USANA Health Sciences has a fifty-two week low of $64.20 and a fifty-two week high of $137.95.
USANA Health Sciences announced that its board has approved a share repurchase program on Tuesday, October 23rd that permits the company to buyback $150.00 million in shares. This buyback authorization permits the company to purchase up to 5.9% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s leadership believes its stock is undervalued.
In other news, Director Myron W. Wentz sold 150,000 shares of the company’s stock in a transaction on Monday, August 6th. The stock was sold at an average price of $131.20, for a total transaction of $19,680,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Myron W. Wentz sold 30,000 shares of the company’s stock in a transaction on Monday, October 1st. The stock was sold at an average price of $119.89, for a total value of $3,596,700.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have bought 19,117 shares of company stock valued at $1,349,965 and have sold 952,919 shares valued at $122,805,265. Corporate insiders own 53.20% of the company’s stock.
A number of institutional investors have recently made changes to their positions in USNA. NEXT Financial Group Inc purchased a new stake in USANA Health Sciences during the 3rd quarter worth $121,000. CAPROCK Group Inc. purchased a new stake in USANA Health Sciences during the 2nd quarter worth $214,000. Amalgamated Bank purchased a new stake in USANA Health Sciences during the 2nd quarter worth $223,000. RNC Capital Management LLC purchased a new stake in USANA Health Sciences during the 2nd quarter worth $231,000. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in USANA Health Sciences during the 1st quarter worth $235,000. 51.48% of the stock is owned by hedge funds and other institutional investors.
About USANA Health Sciences
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.
Recommended Story: What Is An Exchange-Traded Fund (ETF)?
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.